The average one-year price target for Ovid Therapeutics (OVID) was raised to $4.87, a 14.29% increase from the prior $4.26 target dated Feb 21, 2026. This revision reflects an upward shift in analyst estimates (average of multiple targets) and is a modestly positive signal for the stock, though it is an analyst-driven metric rather than company-reported results.
The average one-year price target for Ovid Therapeutics (OVID) was raised to $4.87, a 14.29% increase from the prior $4.26 target dated Feb 21, 2026. This revision reflects an upward shift in analyst estimates (average of multiple targets) and is a modestly positive signal for the stock, though it is an analyst-driven metric rather than company-reported results.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
